New, Helpful Multiple Sclerosis (MS) Therapies with Adverse Side Effects
The following article features new studies on multiple sclerosis (MS) therapies and outlines two studies in particular that test the effectiveness of oral fumarate (BG00012) and alemtuzumab (Campath).
The article points out that the study on oral fumarate (BG00012) was a 24-week study that showed positive results, such as few new gadolinium enhancing (GdE) lesions, fewer enlarging or new T2-hypertense and T1-hypointense lesions, and a reduced annual relapse rate. The article goes on to point out that the patients taking oral fumarate were also more likely to suffer with frequent hot flashes, headache, fatigue and abdominal pain.
The article also takes a look at a study on a monoclonal antibody called alemtubzumab, which is currently used to treat leukemia by depleting white blood cells. The study found that the drug helped reduce MS relapse by nearly 75 percent, but as the article points out, the drug was also associated with very toxic effects on patients.
New MS Therapies Show Promise
Return to the Social Security Disability SSI Benefits Blog
How Do You Get Approved for Disability with Social Security?
How many are Approved at a Social Security Disability Hearing?
Once you are approved for SSD are minor children automatically approved for SSI?
Why is it hard to get approved for social security disability with a mental condition?
How long after you are approved for social security disability do you have to sign up for medicare?